ISELIN, N.J. , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced

- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned BLA submission with U.S. FDA in Q12022 ISELIN, N.J. , Nov. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Live moderated video webcast discussion among members of management and Thought Leaders Firas M. Rahhal, MD and Robert L. Avery, MD on Tuesday, November 16th at 9:00 AM ET ISELIN, N.J. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working

Firas M. Rahhal, MD, will present Phase 3 pivotal data from the NORSE TWO registration trial on Saturday, November 13, 2021 ISELIN, N.J. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved

Outlook Therapeutics management to present on Thursday, November 11, 2021 ISELIN, N.J. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in

Strong safety data from NORSE THREE registration trial consistent with other trials for ONS-5010 and in prior published research ISELIN, N.J. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first

Suber Huang, MD, MBA, FASRS, will present safety data from Outlook Therapeutics’ NORSE THREE registration trial on Tuesday, October 12, 2021 ISELIN, N.J. , Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the

Outlook Therapeutics senior leadership team to provide a company overview and participate on industry panel on Thursday, October 7, 2021 ISELIN, N.J. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of Ophthalmology’s Retina Subspecialty Meeting, RET13 - Section X: Late Breaking Developments, Part II on

Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET ISELIN, N.J. , Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved